Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag pilot study in adults with persistent or chronic primary immune thrombocytopenia
ChiCTR2400080388Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lusutrombopag in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Percentage of subjects with platelet count >=50 x10^9/L at Day 29 or platelet count >=250 x10^9/L within 4 weeks. Started Feb 2024; status: completed.
02
Drugs
lusutrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2400080388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080388.